Edwards Lifesciences Commits to Fair Competition Amid Regulatory Scrutiny, Analyst Upgrades Stock
Portfolio Pulse from Vandana Singh
Edwards Lifesciences Corp (NYSE:EW) is under scrutiny by the European Commission for potential market power abuse. Despite this, the company has reiterated its commitment to fair competition. Amid the investigation, Oppenheimer has upgraded Edwards Lifesciences' stock to Outperform from Perform with a price target of $90, citing an attractive risk-reward profile. The company has a significant opportunity in the Transcatheter Tricuspid Valve Replacement (TTVR) sector, with its product EVOQUE expected to obtain regulatory approvals by the end of 2024.
September 26, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edwards Lifesciences Corp is under regulatory scrutiny but has received an upgrade from Oppenheimer. The company's product EVOQUE is expected to drive growth.
Despite the ongoing regulatory scrutiny, the company's commitment to fair competition and the positive outlook from Oppenheimer, especially regarding the potential of EVOQUE, are likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100